Project Details
| Status | Active |
|---|---|
| Effective start/end date | 11/16/21 → 12/31/26 |
Funding
- Vertex Pharmaceuticals Incorporated: $134,257.36
VX20-121-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G
- Frederick, Carla (PI)
Project: Research